by Anthony Montanarella | Apr 16, 2026 | Company News, Product News
XGen Pharmaceuticals DJB, Inc. is excited for another new product release! Announcing the launch of Eribulin Mesylate Injection! 1 mg/2 mL (0.5 mg/mL) (NDC#39822-2080-1) Eribulin Mesylate Injection “With this launch of Eribulin Mesylate Injection, we are proud to add...
by Anthony Montanarella | Dec 5, 2024 | Company News, News, Product News, Product News
XGen Pharmaceuticals DJB, Inc. is excited to conclude the calendar year with another new product release! Announcing the launch of Edaravone Injection, available in two dosages: 30 mg/100 mL (0.3 mg/mL), 2-pack carton (NDC#39822-4500-2) 60 mg/100 mL (0.6 mg/mL),...
by Anthony Montanarella | Sep 20, 2024 | Company News, News, Product News
Horseheads, New York – August 26, 2024XGen Pharmaceuticals DJB, Inc. (XGen), a leading manufacturer in the generics pharmaceutical industry, is proud to announce that it has achieved full compliance with the Drug Supply Chain Security Act (DSCSA) well ahead of the...
by Anthony Montanarella | Mar 31, 2024 | Company News, Product News
We are excited to announce the launch of Desmopressin Acetate Injection, USP in 40mcg/10mL x 1 vial (NDC#39822-6250-1) and 4mcg/mL x 10 vials (NDC# 39822-6200-2) presentations! XGen Pharmaceuticals DJB, Inc. is pleased to announce the addition of Desmopressin Acetate...
by support@incommandtech.com | Feb 14, 2024 | Company News, Product News
Cyclophosphamide for Injection, USP XGen Pharmaceuticals DJB, Inc. is pleased to announce the addition of Cyclophosphamide for Injection, USP to their expanding product line. Cyclophosphamide for Injection will be available with a 3 year shelf-life in single-dose...
by Anthony Montanarella | Aug 13, 2023 | Company News, Industry Sponsorships
XGen Pharmaceuticals DJB, Inc, is a longtime supporter of the National Pharmacy Purchasing Association. It is our pleasure again to be attending the conference and will be exhibiting at Booth Space 321. We value these opportunities, not only to see familiar faces but...